Media

  • MD Anderson and CureVac enter strategic collaboration to develop novel cancer vaccines on April 16th, 2024
  • Sachet sharing his views on the relevance and timeliness of cancer vaccines. Interview with ABC7 News Bay Area  on Oct 11th  2022.
  • Sachet quoted in an insightful article on preventive use of cancer vaccines in New York Times (pdf) on Oct 10th 2022.

Lab News

  • Dustin McCurry is awarded at the Society of Immunotherapy of Cancer Sparkathon as an emerging leader igniting innovation on Nov 7th 2022.
  • The Shukla Lab officially completes one year at MD Anderson on November 2nd 2022!
  • Tejas Jammihal is invited to speak at the MD Anderson Research Town Hall on October 21st 2022.
  • Sachet Shukla is recognized by Clarivate and named on the Highly Cited Researchers list of 2021 on November 16th 2021.

Research Features

  • What drives exceptionally good responses to checkpoint inhibition in kidney cancer? Fantastic presentation by Tejas at KidneyCAN 2022 in Philly on October 7th 2022.
Clonal neoantigen load and tertiary lymphoid structure formation are associated with exceptional response to immune checkpoint inhibition in clear cell renal cell carcinoma
  • TNBC paper
  • RCC paper with Sabina